PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival

Simple item page
dc.AffiliationOctober university for modern sciences and Arts MSA
dc.contributor.authorEl-Khazragy, Nashwa
dc.contributor.authorGaballah, Ahmed
dc.contributor.authorBakkar, Ashraf
dc.contributor.authorHemida, Eman H.A
dc.contributor.authorSamir, Nehal
dc.contributor.authorTarek, Marwa
dc.contributor.authorAdly, Heba M
dc.contributor.authorSaleh, Saleh A.K
dc.contributor.authorHanna, Demiana H
dc.date.accessioned2023-01-28T09:01:29Z
dc.date.available2023-01-28T09:01:29Z
dc.date.issued2023-04
dc.descriptionSJR 2024 1.018 Q2 H-Index 85
dc.description.abstractBackground: Trastuzumab is an effective therapeutic approach for HER2-positive metastatic breast cancer (BC). However, a considerable number of patients develop resistance along the course of the disease. PTEN rs701848 polymorphisms are associated with an increased risk of developing cancer and have a potential role in predicting drug resistance. Objective: We studied the significance of PTEN rs701848 variants as significant predictors for trastuzumab resistance in HER2-positive metastatic BC patients. Therefore, considering their value in predicting clinical outcomes. Materials and Methods: This case-control study was conducted among female patients with HER2-positive metastatic breast cancer who underwent Trastuzumab therapy during the period from March 2017 to December 2020. PTEN rs701848 genotypes were analyzed in 160 HER2-positive metastatic breast cancer who received Trastuzumab therapy and clinically monitored for therapeutic response. Results: PTEN rs701848 is deemed a significant predictor of Trastuzumab resistance and an independent prognostic factor of progression-free survival (PPFS). In particular, the C allele is associated with increased risk for Trastuzumab resistance and shorter PFS as compared to the homozygous TT genotype. Conclusion: PTEN rs701848 is significant predictor of trastuzumab resistance. Therefore, their value in predicting clinical outcomes is recommendeden_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=29260&tip=sid&clean=0
dc.identifier.citationEl-Khazragy, N., Gaballah, A., Bakkar, A., Hemida, E. H., Samir, N., Tarek, M., Adly, H. M., Saleh, S. A., & Hanna, D. H. (2022). PTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survival. Clinical Breast Cancer, 23(3), e131–e139. https://doi.org/10.1016/j.clbc.2022.12.010
dc.identifier.doihttps://doi.org/10.1016/j.clbc.2022.12.010
dc.identifier.otherhttps://doi.org/10.1016/j.clbc.2022.12.010
dc.identifier.urihttps://tinyurl.com/2ewjxlxw
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesClinical Breast Cancer;Volume 23, Issue 3e131-e139April 2023
dc.subjectHER2-positive,en_US
dc.subjectBreast cancer,en_US
dc.subjectPTEN rs701848,en_US
dc.subjectTrastuzumab,en_US
dc.subjectSurvivalen_US
dc.titlePTEN rs701848 Polymorphism is Associated with Trastuzumab Resistance in HER2-positive Metastatic Breast Cancer and Predicts Progression-free Survivalen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2.0-S1526820922002889-main.pdf
Size:
520.93 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Faculty of Biotechnology Research Paper